Skip to main content
Premium Trial:

Request an Annual Quote

Variantyx Secures $20M Debt Financing to Support Precision Medicine in North America, Europe

NEW YORK – Variantyx said Tuesday that it has secured $20 million in debt financing from Kreos Capital. The genomic analysis company plans to use the additional cash to grow in the North American and European precision medicine markets, particularly in cancer.

Framingham, Massachusetts-based Variantyx offers a proprietary whole-genome analysis platform to support testing and diagnostics for rare genetic disorders, reproductive health, and precision oncology.

"Variantyx has built a unique and advanced platform for precision medicine, and its ability to process the whole genome sets it apart in the genomic diagnostics market. Our funds, which enhance the company's already strong capital position, will allow it to significantly scale up its commercial efforts," Aris Constantinides, general partner of London-based Kreos Capital, said in a statement.

Variantyx completed a $41.5 million Series C-2 funding round earlier this year, which supported the launch of the analysis platform. That built on a $26 million Series C that closed in two stages in 2021.

The company started with a proprietary WGS-based testing method for diagnosing rare inherited and neurological disorders but expanded into oncology and prenatal testing last year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.